At Informa Connect’s Cell & Gene Therapy International 2024 conference, Flagship Operating Partner and Mirai Bio President Hari Pujar presented an overview of the rapid pace of medical advancements and pursuit of new modalities driven by exponential growth in knowledge, capabilities, and understanding. This accelerated pace enables medical breakthroughs but also poses technical challenges, specifically in manufacturing and delivery of new modalities like mRNA and other nucleic acid medicines. Leveraging technological advancements in machine learning, Flagship’s latest company, Mirai Bio, has built an end-to-end platform for the biotech industry that harnesses vast knowledge, data, and tools to design and manufacture near infinite medicines with the highest possibility of translational success against target indications across the body. This relentless drive for innovation at Mirai and across the industry has the promise to expand the boundaries of what is possible exponentially to realize future of nucleic acid medicine.
Related Companies
- Mirai Bio Founded: 2021
